Stay updated on Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.

Latest updates to the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has removed detailed information about the treatment protocol for advanced mucosal melanoma and acral lentiginous melanoma, including eligibility criteria and study specifics, while adding references to acral lentiginous melanoma and a new version revision.SummaryDifference37%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.